Fabrication and characterization of etoposide loaded magnetic polymeric microparticles
Keywords:
poly (ē-caprolactone), solvent evaporation, superparamagnetic, saturation magnetizationAbstract
The purpose of this study is to develop a targeted drug carrier system. Magnetic poly (ē- caprolactone) (PCL) microspheres were prepared using classical oil-in-water solvent evaporation method by loading magnetite nanoparticles and anticancer drug etoposide. The prepared magnetic microspheres were smooth, free flowing, individual and homogenous in nature. Fourier transformed infrared spectroscopy studies revealed the absence of any potential incompatibility of drug with other excipients. DSC studies were conducted to study the state of etoposide in the formulation. Further the magnetic microspheres were characterized for entrapment efficiency, drug loading, invitro release studies and subjected to particle size analysis and scanning electron microscopy. The magnetite nanoparticles were well dispersed in polymer matrix, which are responsible for magnetic response. The magnetic property of the prepared microspheres was measured by using vibrating sample magnetometer. The amount of magnetite in the formulation was estimated quantitatively by atomic absorption spectroscopy which was about 31.5%. The experimental results proved that the magnetic microspheres exhibited superparamagnetic behavior and the saturation magnetization was 7.26 emu/g. The optimized formulations exhibited a narrow size distribution which were below 10 μm and are evident from SEM analysis. Formulation batches prepared with drug/polymer ratio 1:10 showed a maximum encapsulation efficiency and the invitro release profile in phosphate buffer (pH 7.4) solution showed an extended release of etoposide up to 76.25% at the end of 21 day. Histopathological studies proved that the etoposide loaded magnetic microspheres were nontoxic and safe.
References
Saravanan M, Bhaskara K, Gomathinayagam M, Sadasivan Pilai K. Ultrasonically controlled release and targeted delivery of diclofenac sodium via gelatin magnetic microspheres. Int J Pharm. 2004; 283: 71-82.
Widder KJ, Flouret G, Senyei A. Magnetic microspheres:synthesis of a novel parenteral drug carrier. J. Pharm. Sci. 1979; 68(1): 79-82.
Alexiou C, Arnold W, Klein RJ, Parak FJ, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000; 60: 6641 - 8.
Lubbe AS, Bergemann C, Brock J, McClure DG. Physiological aspects in magnetic drug-targeting. J. Magn. Magn. Mater. 1999; 194: 149-155.
Widder KJ, Senyei AE, Ranney DF. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv Pharmacol Chemot. 1979; 16: 213-271.
Wu Y, Guo J, Yang WL, Wang CC, Fu SK. Preparation and characterization of chitosan-poly(acrylic acid) polymer magnetic microspheres. Polymer. 2006; 47: 5287 - 94.
Cregg PJ, Murphy K, Mardinoglu A. Calculation of nanoparticle captures efficiency in magnetic drug targeting. J. Magn. Magn. Mater. 2008; 320: 3272 - 5.
Lin JJ, Chen JS, Haung SJ, Ko JH, Wang YM, Chen TL, Wang LF. Folic acid-pluronic F127 magnetic nanoparticale clusters for combined targeting, diagnosis, and therapy applications. Biomaterials 2009; 30: 5114 - 24.
Cabuil V. Preparation and properties of magnetic nanoparticles. Hubbard, A.T. (Ed), Encyclopedia of Surface and Colloid Science. Marcel Dekker Inc., New York, pp. 4306-21; 2002.
Iannone A, Margin R.L, Walczack T, Federico M, Swartz H.M, Tnansi A, Vannini V. Blood clearance of dextran magnetic particle determined by a non-invasive in vivo ESR method. Magn. Reson. Med. 1991; 22: 435 - 42.
Duhem N, Rolland J, Riva R, Guillet P, Schumers J.M, Gohy J.F, Preat V. Tocol modified glycol chitosan for the oral delivery of poorly soluble drugs. Int. J. Pharm. 2012; 433: 453 - 60.
Yan S, Rao S, Zhu J, Wang Z, Duan Y, Chen X, Yin J. Nanoporous multilayer poly (L)-glutamic acid/chitosan microcapsules for drug delivery. Int.J.Pharm. 2012; 427: 443 - 51.
Sinha V.R, Bansal K, Kaushik R, Kumaria R, Trehan A. Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int. J.Pharm. 2004; 278 (1): 1 - 23.
Hakkarainen M, Albertsson A.C. Heterogenous biodegradation of polycaprolactone – low molecular weight products and surface changes. Macromol. Chem. Phys. 2002; 203: 1357 - 63
Gorna K, Gogolewski S. In vitro degradation of novel medical biodegradable aliphatic polyurethanes based on epsilon-caprolactone and pluronics with various hydrophilicities. Polym. Degrad. Stab. 2002; 75: 113 - 22.
Perez M.H, Zinutti C, Lamprecht A, Ubrich N, Astier A, Hoffman M, Bodmeier R, Maincent P. The preparation and evaluation of poly (epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. J. Control. Release. 2000; 65(3): 429 - 38.
Ihde Dc. Small cell lung cancer. State-of-the-art therapy 1994. Chest 1995; 107(6) (Suppl): 2438 - 85.
Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer. 1998; 34: 1514 - 21.
Wolf S.N, Grosh W.W, Prater K. In vitro pharmacodynamic evaluation of VP-16213 and implications for chemotherapy. Cancer. Chemother. Pharmacol. 1987; 19: 246 - 9.
Wang S, Guo S. Formation mechanism and release behavior of poly(ε- caprolactone) microspheres containing disodium norcantharidate. Eur. J. Pharm and Biopharm. 2008; 69: 1176 – 81.
Yang Y, Park S.B, Ho-Geun Yoon, Huh Y-M, Haam S. Preparation of poly ε-caprolactone nanoparticles containing magnetite for magnetic drug carrier. Int. J. Pharm. 2006; 324: 185 - 90.
Fengxia Li, Xiaoli Li, Bin Li. Preparation of magnetic polylactic acid microspheres and investigation of its releasing property for loading curcumin. J. Magn. Magn. Mater. 2011; 323: 2770 - 75.
Rita JM, Pradip KG, Manish LU, Rayasa SR. Thermoreversible mucoadhesive gel for nasal delivery of sumatryptan. AAPS Pharm Sci Tech. 2006; 7: E1 - E7.
Benoit MA, Baras B, Gillard J. Preparation and characterization of protein loaded poly (ε-caprolactone) microparticles for oral vaccine delivery. Int.J.Pharm. 1999;184: 73 - 84.
Lamprecht A, Ubrich N, Hombriero Perez M, et al. Biodegradable monodispersed nano particles prepared by pressure homogenization emulsification. Int. J. Pharm. 1999; 184: 97 - 105.
Zaitsev VS, Filimonov DS, Presnyakov IA, Gazvbivo RF. Physical and chemical property of magnetite and magnetite-polymer nanoparticles and their colloidal dispersion. B.Colloidal Interface Sci. 2012; 49 - 57.
Yamaura M, Camilo RL, Sampaio LC, Macedo MA, Nakamura M, Toma HE. Preparation and characterization of (3-aminopropyl)triethoxysilane-coated magnetite nanoparticles. J. Magn. Magn. Mater. 2004; 279: 210 - 217.
Gupta PK, Hung CT. Magnetically controlled targeted micro carrier systems. Life Sci. 1989; 44: 175 - 86.
Zhou SB, Deng XM, Li XH. Investigation on a novel core-coated microspheres protein delivery system. J. Controlled release. 2001; 75: 27 - 36.
Bodmeier R, Chem H. The preparation and characterization of microspheres containing the anti-inflammatory agents indomethacin, ibuprofen and ketoprofen. J. Controlled Release. 1989; 10: 167 - 75.
Ammoury N, Dubrasquet M, Fessi H, Devissaguet JP, Puisieux F, Beusio S. Indomethacin -loaded poly(D,L-lactide) nanocapsules, protection from gastrointestinal ulcerations and anti-inflammatory activity evaluation in rats. Clin. Mater. 13: 121 - 30.
Dhanaraju MD, Gopinath D, Rafiuddin Ahmed M, Jayakumar R, Vamsadhara C. Characterization of polymeric(ε-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids. J. Biomed. Matr. Research. 2006; 76(1): 63 - 72.
